Tempus AI

Tempus AI OCF/Debt

The Operating Cash Flow to Debt Ratio of Tempus AI (TEM) as of Oct 16, 2026 is -17.59 %. In the previous year, Operating Cash Flow to Debt Ratio was -43.42 % — a change of -59.47% (higher).

OCF/Debt

-17.59 %

YoY

-59.47%

Last updated:

Operating Cash Flow to Debt Ratio of Tempus AI is 2025 -17.59 % . Operating Cash Flow to Debt Ratio of Tempus AI was 2024 -43.42 % . It decreases by -59.47% higher compared to the previous year.

The Tempus AI OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
-4,518.17 USD
Jan 1, 2020
-82.15 USD
Jan 1, 2021
-88.72 USD
Jan 1, 2022
-43.15 USD
Jan 1, 2023
-47.67 USD
Jan 1, 2024
-43.42 USD
Jan 1, 2025
-17.59 USD
The Tempus AI OCF/Debt history
YEAROCF/DebtYoY
-17.59 %-59.47%
-43.42 %-8.92%
-47.67 %+10.47%
-43.15 %-51.36%
-88.72 %+7.99%
-82.15 %-98.18%
-4,518.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc, listed on the stock market with ticker TEM and ISIN US88023B1035, is a U.S.-based company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Headquartered in Chicago, the company employs approximately 3,800 people. Tempus AI Inc completed its initial public offering (IPO) on June 14, 2024. The company's website is www.tempus.com. Tempus AI Inc provides next-generation diagnostics across multiple disease areas, utilizing data and analytics to support personalized medicine. Its product offerings include genomics, data analytics, and artificial intelligence applications. The genomics division operates laboratories that deliver next-generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and various anatomic and molecular pathology testing services. The AI applications division focuses on developing algorithmic diagnostics, software as a medical device, and clinical decision support tools. The company's primary AI platform, Next, uses machine learning to analyze routinely generated data, aiming to proactively identify and address care gaps for patients in oncology and cardiology. Tempus AI Inc is positioned as a technology company within the life sciences sector, leveraging advanced data capabilities to enhance medical care and treatment personalization. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Operating Cash Flow to Debt Ratio of Tempus AI is -17.59 % in 2025.

Operating Cash Flow to Debt Ratio of Tempus AI changed from -43.42 % to -17.59 %, representing a -59.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Tempus AI since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Tempus AI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tempus AI

All Key Metrics — Tempus AI